Kymera Therapeutics (KYMR) Barclays 28th Annual Global Healthcare Conference summary

Company overview and strategy

• Focused on targeted protein degradation, especially for immunology targets with unmet needs.

• Built a team of 250+ with strong capabilities in lead discovery and chemistry.

• Aims to introduce one new program annually, with the next likely in immunology in the second half of this year.

• Pipeline prioritizes targets with proven biology but lacking effective small molecule solutions.

• Company is capitalized with $1.6 billion, providing runway into 2029 for broad clinical development.

STAT6 program highlights

• STAT6 program showed strong target degradation and safety in healthy volunteers and patients.

• Phase II trials in atopic dermatitis and asthma are underway, with data expected by mid-2027 and end of 2027, respectively.

• Oral STAT6 inhibitor aims to match or exceed efficacy of injectable biologics like Dupixent, offering a less invasive alternative.

• Late-breaker presentations at AAD are building clinical and investor excitement.

• Early data in patients with comorbid asthma showed meaningful reductions, supporting broader potential.

Pipeline expansion and future plans

• IRF5 program targets diseases like lupus, RA, and IBD, with healthy volunteer data expected by year-end.

• IRF5 is a challenging, genetically validated target; first patient studies likely in lupus.

• Strategy is to expand indications sequentially, prioritizing those with the largest unmet needs and market potential.

• Plans to move into pediatric populations as quickly as regulatory pathways allow.

• Target selection focuses on known biology, large unmet needs, and preference for oral therapies over biologics.